Last $27.73 USD
Change Today +0.28 / 1.02%
Volume 85.4K
HPTX On Other Exchanges
As of 8:10 PM 02/26/15 All times are local (Market data is delayed by at least 15 minutes).

hyperion therapeutics inc (HPTX) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $32.98
52 Week Low
12/1/14 - $20.23
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

hyperion therapeutics inc (HPTX) Related Bloomberg News

View More Bloomberg News

hyperion therapeutics inc (HPTX) Related Businessweek News

No Related Businessweek News Found

hyperion therapeutics inc (HPTX) Details

Hyperion Therapeutics, Inc., a commercial biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases and hepatology. The company’s products include RAVICTI, which is used as a nitrogen-binding agent for chronic management of adult and pediatric urea cycle disorder (UCD) patients greater than two years of age, who cannot be managed by dietary protein restriction and/or amino acid supplementation alone; and BUPHENYL, an FDA-approved therapy for treatment of three UCD subtypes. It is also developing glycerol phenylbutyrate for the potential treatment of hepatic encephalopathy. The company was founded in 2006 and is headquartered in Brisbane, California.

54 Employees
Last Reported Date: 03/7/14
Founded in 2006

hyperion therapeutics inc (HPTX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $575.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $347.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $375.0K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $347.0K
Chief Legal & Compliance Officer, Senior Vice...
Total Annual Compensation: $195.9K
Compensation as of Fiscal Year 2013.

hyperion therapeutics inc (HPTX) Key Developments

Hyperion Therapeutics, Inc. to Report Q4, 2014 Results on Feb 26, 2015

Hyperion Therapeutics, Inc. announced that they will report Q4, 2014 results at 4:30 PM, US Eastern Standard Time on Feb 26, 2015

Hyperion Therapeutics, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Hyperion Therapeutics, Inc., Q4 2014 Earnings Call, Feb 26, 2015

Hyperion Therapeutics Enters into Completion of Phase III Clinical Trial, Option and Mutual Release Agreement with Clal Biotechnology Industries Ltd. and Yeda Research and Development Company Ltd

Hyperion Therapeutics, Inc. announced that it has amicably resolved its disputes, and entered into a completion of phase III clinical trial, option and mutual release agreement with Clal Biotechnology Industries Ltd. (CBI) and Yeda Research and Development Company Ltd. (Yeda) regarding DiaPep277, a product candidate developed by Andromeda Biotech Ltd., a company which Hyperion acquired from CBI in June 2014. Hyperion will complete the ongoing DIA-AID 2 phase 3 clinical trial of DiaPep277 to treat new onset Type 1 diabetes and will not take DiaPep277 forward beyond completion of the DIA-AID 2 trial.  Hyperion's estimated budget for completion of the DIA-AID 2 trial remains unchanged at $10.5 million. CBI will have an option to acquire Andromeda, which option expires September 30, 2015. CBI will pay a nonrefundable option payment of $2.5 million at signing, payable in shares of Hyperion stock currently held by CBI. Subject to agreed restrictions, a steering committee consisting of representatives from CBI, Yeda and Hyperion, will oversee and direct the completion of the trial, the analysis of its results, and interactions with regulatory authorities. Hyperion intends to use the option payment to offset any potential increases to the DIA-AID2 trial budget incurred at the steering committee's direction. Any increases to this budget beyond $2.25 million, if incurred at the steering committee's direction, will be reimbursed by CBI. If CBI exercises the option, CBI will pay an option exercise price of $3.5 million, payable in shares of Hyperion stock currently held by CBI. In addition, if the option is exercised, then Andromeda will be obligated to pay Hyperion future contingent payments if and to the extent it or its shareholders receive revenues or certain other proceeds, which are capped at $36.5 million. This amount, together with the option exercise price that Hyperion may receive, approximates the total amount Hyperion will have invested in Andromeda by the option exercise date. If CBI does not exercise the option, the Agreement provides for DiaPep277 intellectual property rights to revert to Yeda. Mutual releases of DiaPep277-related claims were exchanged among Hyperion, Andromeda, CBI, Yeda and Teva Pharmaceutical Industries Ltd.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HPTX:US $27.73 USD +0.28

HPTX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HPTX.
View Industry Companies

Industry Analysis


Industry Average

Valuation HPTX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.6x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERION THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at